botulinum toxin type
Recently Published Documents


TOTAL DOCUMENTS

2639
(FIVE YEARS 458)

H-INDEX

84
(FIVE YEARS 6)

2022 ◽  
Vol 269 ◽  
pp. 218-228
Author(s):  
Soysal Bas ◽  
Ramazan Ucak ◽  
Mert Sizmaz ◽  
Seyhan Hascicek ◽  
Semra H. Karsidag

Author(s):  
Antônio Alcemar Beck ◽  
Letícia Bisso Paz ◽  
Maria Inês Frank ◽  
Ana Martiele Engelmann ◽  
Alexandre Krause ◽  
...  

2021 ◽  
Vol 7 (12) ◽  
pp. 112299-112312
Author(s):  
Kelly Khristiny dos Santos Mady ◽  
Maria Laura Farias dos Santos ◽  
Paulo Victor Coelho da Silva ◽  
Rahyja Teixeira dos Santos ◽  
Maria Nilzangela da Silva

2021 ◽  
pp. 568-573
Author(s):  
Mette Soelberg Schjødt ◽  
Rikke Bech ◽  
Anne Braae Olesen

COVID-19 has been associated with acral ischemia and digital necrosis. Standard treatment of acral ischemia and digital or acral necrosis includes ongoing therapy with vasodilators and anticoagulants. However, these treatments are not always efficient to avoid the progression of necroses, which in the worst case can lead to amputation. Here, we report a case in which interdigital Botox<sup>®</sup> (botulinum toxin type A) nerve cord injection stopped the progression of acral necroses arising from an underlying vasculopathy due to COVID-19. Moreover, Botox<sup>®</sup> injection eliminated inflammation in the affected acral area within 2 weeks. This is the first case report to suggest Botox<sup>®</sup> injection as a new and improving treatment for acral necroses due to COVID-19.


2021 ◽  
Vol 2 (4) ◽  
pp. 189-202
Author(s):  
Alexey L. Kurenkov ◽  
Oleg V. Agranovich ◽  
Lyudmila M. Kuzenkova ◽  
Lusine G. Khachatryan ◽  
Vladimir M. Kenis ◽  
...  

Introduction. In patients with infantile cerebral palsy (CP), botulinum therapy is used to treat both muscle tone disorders and sialorrhea. Therefore, it is logical to use one preparation of botulinum toxin type A to treat spasticity and sialorrhea in one injection procedure. The aim of the work is to conduct a retrospective analysis of data from 15 centres that treat patients with cerebral palsy and use the botulinum therapy method to determine the optimal doses of IncobotulinumtoxinA (IBTA) for the treatment of spasticity and chronic sialorrhea in real clinical practice. Materials and methods. The treatment results of 389 children with cerebral palsy (including 211 (54.2%) boys) with IBTA were analyzed. The majority were children with bilateral forms of cerebral palsy - 312 (80.2%). The average age of the patients was 5.27 ± 3.71 years, the average weight of the patients was 18.8 ± 10.9 kg. Results. The total dose of IBTA in the group of 389 patients with cerebral palsy for the treatment of spasticity was 163.74 ± 80.65 U (25-550; 95% CI 155.7-171.7) and 10.4 ± 5.4 U/kg body weight (1,25-29.7; 95% CI 9.8-10.9). The total dose of IBTA in the group of patients with cerebral palsy with simultaneous treatment of spasticity and chronic sialorrhea (n = 16) was significantly higher: 267.18 ± 124.57 U (115-570; 95% CI 200.8-333.6) and 13, 0 ± 7.1 U/kg (5.8-24.6; 95% CI 9.2-16.8). In the lower extremities, the most frequent target muscles were the gastrocnemius (55.0% of cases; 95% CI 49.9-60.0) and semitendinosus / semimembranous muscle (46.3% of cases; 95% CI 41.2-51.4 ), and in the upper limbs - pronator teres (48.6% of cases; 95% CI 43.5-53.7) and biceps brachii (28.8% of cases; 95% CI 24.3-33.6). Limitations of the study. The limitations of our work are the use of an open retrospective study format, a relatively small sample of patients with chronic sialorrhea, the absence of long-term follow-up of patients and the results of repeated IBTA injections. Conclusion. If it is necessary to use botulinum therapy for the treatment of spasticity and sialorrhea in a child with CP, it is optimal to use the product IncobotulinumtoxinA, which will allow correction of two pathological manifestations in one procedure and can shorten the intervals between repeated injection cycles.


2021 ◽  
Vol 9 ◽  
Author(s):  
Nicole Middaugh ◽  
Leslie Edwards ◽  
Kevin Chatham-Stephens ◽  
D. Fermin Arguello

Outbreaks of wound botulism are rare, but clinicians and health departments should maintain suspicion for signs, symptoms, and risk factors of wound botulism among persons who inject drugs in order to initiate treatment quickly. This report describes an outbreak of three wound botulism cases among persons in two adjacent counties who injected drugs. Provisional information about these cases was previously published in the CDC National Botulism Surveillance Summary. All three cases in this outbreak were laboratory-confirmed, including one case with detection of botulinum toxin type A in a wound culture sample taken 43 days after last possible heroin exposure. Findings highlight the delay in diagnosis which led to prolonged hospitalization and the persistence of botulinum toxin in one patient.


2021 ◽  
Author(s):  
Yongjae Yoo ◽  
Chang-Soon Lee ◽  
Jungsoo Kim ◽  
Dongwon Jo ◽  
Jee Youn Moon

Background The present study was designed to test the hypothesis that botulinum toxin would prolong the duration of a lumbar sympathetic block measured through a sustained increase in skin temperature. The authors performed a randomized, double-blind, controlled trial to investigate the clinical outcome of botulinum toxin type A for lumbar sympathetic ganglion block in patients with complex regional pain syndrome. Methods Lumbar sympathetic ganglion block was conducted in patients with lower-extremity complex regional pain syndrome using 75 IU of botulinum toxin type A (botulinum toxin group) and local anesthetic (control group). The primary outcome was the change in the relative temperature difference on the blocked sole compared with the contralateral sole at 1 postoperative month. The secondary outcomes were the 3-month changes in relative temperature differences, as well as the pain intensity changes. Results A total of 48 participants (N = 24/group) were randomly assigned. The change in relative temperature increase was higher in the botulinum toxin group than in the control group (1.0°C ± 1.3 vs. 0.1°C ± 0.8, respectively; difference: 0.9°C [95% CI, 0.3 to 1.5]; P = 0.006), which was maintained at 3 months (1.1°C ± 0.8 vs. –0.2°C ± 1.2, respectively; P = 0.009). Moreover, pain intensity was greatly reduced in the botulinum toxin group compared with the control group at 1 month (–2.2 ± 1.0 vs. –1.0 ± 1.6, respectively; P = 0.003) and 3 months (–2.0 ± 1.0 vs. –0.6 ± 1.6, respectively; P = 0.003). There were no severe adverse events pertinent to botulinum toxin injection. Conclusions In patients with complex regional pain syndrome, lumbar sympathetic ganglion block using botulinum toxin type A increased the temperature of the affected foot for 3 months and also reduced the pain. Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New


Medicine ◽  
2021 ◽  
Vol 100 (49) ◽  
pp. e27787
Author(s):  
Xiaoshuang Guo ◽  
Tongtong Li ◽  
Ye Wang ◽  
Xiaolei Jin

2021 ◽  
Vol 1 (06) ◽  
Author(s):  
Eliane Xavier da Rosa Bugni ◽  
Alex Giacomini

Botulinum Toxin type A has become a great ally in aesthetic procedures because it is a very efficient non-surgical, aesthetic-therapeutic procedure. Known and much sought after for the result it provides in facial harmonization, by smoothing expression lines caused by repeated contractions carried out over the years, it has increased the demand for the technique, and with that, some complications and light, but transient complications arose. Thus, the objective of this article is to understand the process of application of botulinum toxin type A, its effects and complications (intercurrences) that may arise when not performing the technique as recommended, in addition to reviewing the literature and the protocol for applying the Botulinum toxin type A. The bibliographic research method, literature review of articles from the year 2000, in English and Portuguese, in search platforms of Scielo, Pubmed, Academic Google, atlas, dissertations and theses. Respecting the reapplication time is essential not only for complications, but also the patient's individuality, outlining a safe and effective path to avoid unwanted effects, thus ensuring a successful and attractive procedure both in the eyes of the professional and in the eyes of the clients .


Sign in / Sign up

Export Citation Format

Share Document